Overview

• U.S. chemicals producer's Q1 revenue rose 1% yr/yr, slightly beating analyst expectations

• Adjusted EPS for Q1 beat consensus, despite falling from prior-year levels

• Company received $287 mln from Kuan Yin property sale, used to pay down debt

Outlook

• Chemours sees Q2 net sales rising 15%-20% sequentially, adjusted EBITDA $220 mln-$250 mln

• Company expects 2026 net sales to grow 3%-5%, adjusted EBITDA $800 mln-$900 mln

Result Drivers

• TSS SEGMENT STRENGTH - Record sales and Adjusted EBITDA in Thermal & Specialized Solutions, driven by higher pricing and volumes in Opteon and Freon refrigerants

• TT AND APM WEAKNESS - Lower volumes and weaker end markets in Titanium Technologies and Advanced Performance Materials weighed on results

• HIGHER COSTS - Increased financing and SG&A expenses contributed to a larger net loss

Company press release: ID:nPn7N4GYra

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Sales	Slight Beat*	$1.38 bln	$1.39 bln (6 Analysts)
Q1 Adjusted EPS	Beat	$0.05	-$0.05 (8 Analysts)
Q1 Adjusted Net Income	Beat	$8 mln	-$5.56 mln (5 Analysts)
Q1 Adjusted EBITDA	Beat	$169 mln	$138.09 mln (6 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the diversified chemicals peer group is "buy."

• Wall Street's median 12-month price target for Chemours Co is $23.00, about 17.7% below its May 5 closing price of $27.94

• The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 9 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.